AUTHOR
Mick Weinstein
You may also like
In June, the American Society of Clinical Oncology (ASCO) hosted its 60th Annual Meeting, drawing over 40,000 attendees from around the globe. This year’s event largely focused on validating revolutionary treatment categories like Chimeric antigen receptor (CAR) T-cell therapies and antibody drug conjugates (ADCs). Given proven clinical benefits across a wider array of cancer types, we expect these novel treatment categories to become increasingly important in the fight against cancer and the growth profiles of select companies in the healthcare space.
Investors allocate capital based on growth prospects
Debt, NPR.org Four things this graph says about the world: Ratings matter, except when they don’t. Yes, interest rates tend to increase as ratings fall. But
Shares of Apple (AAPL) had their worst day in nearly four years today as the stock dropped more than six percent and […]